journal article·2025-03Open access

Tumor Microenvironment‐Driven Structural Transformation of Vanadium‐Based MXenzymes to Amplify Oxidative Stress for Multimodal Tumor Therapy

Hai Zhu, Tinghua Li, Xinhao Peng, Xiaoxian Zhang, Xuequan Zhang, Qiusheng Wang, Lei Lei, Jun Zhang, Bin He, Jun Cao

Advanced Science· Volume 12· Issue 11

Abstract

Abstract MXenzymes, a promising class of catalytic therapeutic material, offer great potential for tumor treatment, but they encounter significant obstacles due to suboptimal catalytic efficiency and kinetics in the tumor microenvironment (TME). Herein, this study draws inspiration from the electronic structure of transition metal vanadium, proposing the leverage of TME specific‐features to induce structural transformations in sheet‐like vanadium carbide MXenzymes (TVMz). These transformations trigger cascading catalytic reactions that amplify oxidative stress, thereby significantly enhancing multimodal tumor therapy. Specifically, the engineered HTVMz, coated with hyaluronic acid, exhibits good stability and generates a thermal effect under NIR‐II laser irradiation. The thermal effect, combined with TME characteristics, facilities a structural transformation into ultra‐small vanadium oxide nanozymes (VO x ). The enlarged surface area of VO x substantially enhances ROS regeneration and amplifies oxidative stress, which promotes lysosomal permeability and induces endoplasmic reticulum stress. The high‐valent vanadium in VO x interacts with intracellular glutathione, disrupting redox homeostasis and intensifying oxidative stress further. These amplifications accelerate tumor apoptosis, induce ferroptosis, and suppress HSP90 expression. Consequently, the heightened thermal sensitivity of HTVMz synergistically promotes tumor cell death via multimodal therapeutic pathways. This study presents an innovative strategy for tumor catalytic therapy by manipulating MXenzymes structures, advancing the field of catalytic therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · MXene and MAX Phase Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Oncology Affiliated Hospital of Southwest Jiaotong University/The Third People's Hospital of Chengdu Chengdu 610031 China

Medical Research Center Affiliated Hospital of Southwest Jiaotong University/The Third people's Hospital of Chengdu Chengdu 610031 China

National Engineering Research Center for Biomaterials College of Biomedical Engineering Sichuan University Chengdu 610064 China

Funding

Chengdu Science and Technology Bureau · Natural Science Foundation of Sichuan Province

References (54)

Show source-provided references
1. 10.1016/j.jddst.2024.10559910.1016/j.jddst.2024.105599 ↗
2. 10.1016/j.medj.2024.03.00110.1016/j.medj.2024.03.001 ↗
3. 10.1002/advs.20230603110.1002/advs.202306031 ↗
4. 10.1038/s41467-023-44665-210.1038/s41467-023-44665-2 ↗
5. 10.1002/adfm.20231456810.1002/adfm.202314568 ↗
6. 10.1016/j.nantod.2024.10224410.1016/j.nantod.2024.102244 ↗
7. 10.1016/j.cej.2024.14856110.1016/j.cej.2024.148561 ↗
8. 10.1002/advs.20230597910.1002/advs.202305979 ↗
9. 10.1038/s41467-018-03903-810.1038/s41467-018-03903-8 ↗
10. 10.1016/j.ccr.2024.21593710.1016/j.ccr.2024.215937 ↗
11. 10.1002/anie.20231660610.1002/anie.202316606 ↗
12. 10.1126/science.abf158110.1126/science.abf1581 ↗
13. 10.1002/adma.20230711510.1002/adma.202307115 ↗
14. 10.1002/adfm.20221184610.1002/adfm.202211846 ↗
15. 10.1016/j.talanta.2023.12487210.1016/j.talanta.2023.124872 ↗
16. 10.1002/adma.20240111110.1002/adma.202401111 ↗
17. 10.1002/adfm.20231399710.1002/adfm.202313997 ↗
18. 10.1016/j.biomaterials.2024.12252310.1016/j.biomaterials.2024.122523 ↗
19. 10.1038/s41467-021-22278-x10.1038/s41467-021-22278-x ↗
20. 10.1021/acsnano.3c0152710.1021/acsnano.3c01527 ↗
21. 10.1016/j.jconrel.2024.01.04910.1016/j.jconrel.2024.01.049 ↗
22. 10.1039/C9NR03020D10.1039/C9NR03020D ↗
23. 10.1016/j.jmat.2023.08.00310.1016/j.jmat.2023.08.003 ↗
24. 10.1016/j.ccr.2023.21554210.1016/j.ccr.2023.215542 ↗
25. 10.1016/j.cej.2024.14910710.1016/j.cej.2024.149107 ↗
26. 10.1002/smll.20220174010.1002/smll.202201740 ↗
27. 10.1007/s40820-022-00958-710.1007/s40820-022-00958-7 ↗
28. 10.1016/j.cej.2024.15186710.1016/j.cej.2024.151867 ↗
29. 10.1021/acs.chemmater.1c0350810.1021/acs.chemmater.1c03508 ↗
30. 10.1021/acssuschemeng.3c0029810.1021/acssuschemeng.3c00298 ↗
31. 10.1038/s41467-022-31106-910.1038/s41467-022-31106-9 ↗
32. 10.1002/adma.20231100210.1002/adma.202311002 ↗
33. 10.1002/adma.20220969210.1002/adma.202209692 ↗
34. 10.1002/advs.20200027210.1002/advs.202000272 ↗
35. 10.1039/D2CS00236A10.1039/D2CS00236A ↗
36. 10.1002/adfm.20221274010.1002/adfm.202212740 ↗
37. Zeng X. · ACS Appl. Mater. Interfaces · 2023 · 15
38. 10.1002/adfm.20231211610.1002/adfm.202312116 ↗
39. 10.1002/advs.20230387210.1002/advs.202303872 ↗
40. 10.1080/15548627.2022.211163510.1080/15548627.2022.2111635 ↗
41. 10.1016/j.scib.2020.10.02110.1016/j.scib.2020.10.021 ↗
42. 10.1016/j.bbcan.2018.04.01010.1016/j.bbcan.2018.04.010 ↗
43. 10.1002/adma.20220004810.1002/adma.202200048 ↗
44. 10.1016/j.actbio.2021.11.04210.1016/j.actbio.2021.11.042 ↗
45. 10.1002/smll.20230958310.1002/smll.202309583 ↗
46. 10.1002/smll.20210391910.1002/smll.202103919 ↗
47. 10.1038/s41467-023-43870-310.1038/s41467-023-43870-3 ↗
48. 10.1039/D0NR02800B10.1039/D0NR02800B ↗
49. 10.1002/adma.20230255910.1002/adma.202302559 ↗
50. 10.1002/adma.20221046410.1002/adma.202210464 ↗
51. 10.1038/s41551-022-00862-w10.1038/s41551-022-00862-w ↗
52. 10.1039/D2TB01783K10.1039/D2TB01783K ↗
53. 10.1021/acs.nanolett.4c0402610.1021/acs.nanolett.4c04026 ↗
54. 10.1038/s41596-024-01034-710.1038/s41596-024-01034-7 ↗